VPH vs. WLLW, CTX, DN, LABS, MDP, AEZS, TMD, and ATE
Should you be buying Valeo Pharma stock or one of its competitors? The main competitors of Valeo Pharma include Willow Biosciences (WLLW), Crescita Therapeutics (CTX), Delta 9 Cannabis (DN), MediPharm Labs (LABS), Medexus Pharmaceuticals (MDP), Aeterna Zentaris (AEZS), Titan Medical (TMD), and Antibe Therapeutics (ATE). These companies are all part of the "medical" sector.
Valeo Pharma (TSE:VPH) and Willow Biosciences (TSE:WLLW) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.
Willow Biosciences has a net margin of 0.00% compared to Valeo Pharma's net margin of -52.37%. Valeo Pharma's return on equity of 0.00% beat Willow Biosciences' return on equity.
Willow Biosciences has lower revenue, but higher earnings than Valeo Pharma. Willow Biosciences is trading at a lower price-to-earnings ratio than Valeo Pharma, indicating that it is currently the more affordable of the two stocks.
Valeo Pharma has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, Willow Biosciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
Willow Biosciences received 13 more outperform votes than Valeo Pharma when rated by MarketBeat users. However, 100.00% of users gave Valeo Pharma an outperform vote while only 82.35% of users gave Willow Biosciences an outperform vote.
In the previous week, Valeo Pharma's average media sentiment score of 0.00 equaled Willow Biosciences'average media sentiment score.
7.2% of Valeo Pharma shares are held by institutional investors. Comparatively, 0.1% of Willow Biosciences shares are held by institutional investors. 48.2% of Valeo Pharma shares are held by company insiders. Comparatively, 27.3% of Willow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Valeo Pharma beats Willow Biosciences on 8 of the 13 factors compared between the two stocks.
Get Valeo Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Valeo Pharma Competitors List
Related Companies and Tools
